The emerging role of speckle-type POZ protein (SPOP) in cancer development

Ram-Shankar Mani1

  • 1Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA; Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.

Drug Discovery Today
|July 25, 2014
PubMed

Insights

Speckle-type POZ protein (SPOP) mutations are common in prostate cancer and define a unique subtype. These alterations impact the androgen-signaling pathway, contributing to cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Speckle-type POZ (pox virus and zinc finger protein) protein (SPOP) functions as an E3 ubiquitin ligase adaptor.
  • SPOP is frequently mutated in prostate and endometrial cancers, with mutations clustering in the MATH domain, potentially affecting substrate binding.
  • SPOP mutations are mutually exclusive with ETS gene rearrangements in prostate cancer, identifying a distinct molecular subclass.

Purpose of the Study:

  • To investigate the role of SPOP mutations in prostate cancer development.
  • To understand how SPOP mutations affect the androgen-signaling pathway.

Main Methods:

  • Analysis of SPOP mutation data in prostate cancer.
  • Investigation of the impact of SPOP mutations on protein interactions and degradation.
  • Examination of the androgen-signaling pathway in the context of SPOP mutations.

Main Results:

  • SPOP mutations define a distinct molecular subclass of prostate cancer.
  • Mutations in SPOP alter the steady-state levels of key components within the androgen-signaling pathway.
  • These alterations contribute to prostate cancer development.

Conclusions:

  • SPOP mutations play a significant role in prostate cancer pathogenesis.
  • Targeting the androgen-signaling pathway may be a therapeutic strategy for SPOP-mutated prostate cancers.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Tumor Progression02:07

Tumor Progression

3.1K